Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 10/1999

01-10-1999

Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells

Authors: Takuzou Moriyama, Hiroaki Kataoka, Ryouichi Hamasuna, Etsuo Yoshida, Tetsuro Sameshima, Tsutomu Iseda, Kiyotaka Yokogami, Shinichi Nakano, Masashi Koono, Shinichiro Wakisaka

Published in: Clinical & Experimental Metastasis | Issue 10/1999

Login to get access
Metadata
Title
Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells
Authors
Takuzou Moriyama
Hiroaki Kataoka
Ryouichi Hamasuna
Etsuo Yoshida
Tetsuro Sameshima
Tsutomu Iseda
Kiyotaka Yokogami
Shinichi Nakano
Masashi Koono
Shinichiro Wakisaka
Publication date
01-10-1999
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 10/1999
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1006729611241

Other articles of this Issue 10/1999

Clinical & Experimental Metastasis 10/1999 Go to the issue

OriginalPaper

Autocrine motility factor (neuroleukin, phosphohexose isomerase) induces cell movement through 12-lipoxygenase-dependent tyrosine phosphorylation and serine dephosphorylation events

OriginalPaper

Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines

OriginalPaper

Biological properties associated with the enhanced lung-colonizing potential in a B16 murine melanoma line grown in a medium conditioned by syngeneic Corynebacterium parvum-elicited macrophages

OriginalPaper

Stathmin is involved in S100A4-mediated regulation of cell cycle progression

OriginalPaper

Highly metastatic variant of a mouse colon carcinoma cell line, LM17 and its response to GM-CSF gene therapy

OriginalPaper

A model of spontaneous lung metastases visualised in fresh host tissue by green fluorescent protein expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits